Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience.

Autor:	Balhareth AS; Colorectal Section, Department of Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia., AlQattan AS; Department of Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia., Alshaqaq HM; College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia., Alkhalifa AM; Department of General Surgery, King Fahad University Hospital, Khobar, Saudi Arabia., Al Abdrabalnabi AA; College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia., Alnamlah MS; College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia., MacNamara D; Department of Colorectal Surgery Beaumont Hospital and National Clinical Programme in Surgery, RCSI, Ireland.
Jazyk:	angličtina
Zdroj:	Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2022 Apr 04; Vol. 77, pp. 103559. Date of Electronic Publication: 2022 Apr 04 (Print Publication: 2022).
DOI:	10.1016/j.amsu.2022.103559
Abstrakt:	Background: Isolated pulmonary metastasis (IPM) is a rare entity that accounts for 10% of pulmonary metastases seen in colorectal cancer (CRC). This study aims to evaluate the overall 5-year survival of IPM originating from CRC and identify potential prognostic factors affecting the overall survival (OS). Methods: A retrospective cohort study conducted in a tertiary care center. The study included all patients diagnosed with CRC aged 18-75 years who underwent primary tumor resection with curative intent between 2008 and 2015, and developed IPM. Patients with no follow-up and those with extra-pulmonary metastases were excluded. Results: The prevalence of IPM in the overall CRC cases was 4.18% (20/478 patients). The mean age of patients with IPM was 52.7 ± 12.9 years. Ten patients had synchronous IPM (50%), thirteen had unilateral (65%), and eleven underwent metastasectomy (55%). The 5-year OS was 40%, and the mean OS was 3.12 ± 1.85 years. Several factors were found to be associated with a favorable outcome, which include unilateral IPM (3.69 vs. 2.07 years; P = 0.024), metachronous (4.25 vs. 2.14 years; P = 0.017), metastasectomy (4.81 vs. 1.83 years; P = 0.005). In addition, mortality was likely to be decreased by more than 90% after metastasectomy (unadjusted odds ratio = 0.071; 95% confidence interval [CI] = 0.01-0.8; P = 0.032). Conclusions: Forty percent of the included patients survived the 5-year follow-up. Better survival was associated with the metastases being unilateral, metachronous, and metastasectomy. Mortality was lower in patients with pulmonary recurrence after metastasectomy. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu